Latest Governance News

Nufarm Limited’s 2025 AGM revealed a resilient FY24 performance despite industry headwinds, with strong growth in omega-3 canola and strategic cost-saving initiatives setting the stage for future expansion.

Nufarm’s 2025 AGM revealed a resilient FY24 performance despite industry headwinds, with strategic investments in omega-3 canola, biofuels, and cost-saving initiatives setting the stage for growth in FY25.

Basin Energy has secured government approval for its Trollberget project in Sweden, doubling its landholdings in the Arvidsjaur-Arjeplog uranium district and setting the stage for promising exploration results expected in early 2025.

The Takeovers Panel has declined to investigate Keybridge Capital’s applications alleging shareholder associations and takeover law breaches, clearing the way for an upcoming board replacement vote.

VanEck Investments Limited has announced final dividends for a suite of its exchange traded funds, with payments scheduled for mid-February. Investors are reminded of the dividend reinvestment plan and upcoming tax details.

Entyr Limited has received a $3.79 million R&D tax incentive payment for its innovative thermal desorption project targeting rubber waste, reinforcing its position in sustainable tyre recycling technology.

Redivium Limited remains suspended from ASX trading following a failed entitlement offer and key director resignations, raising fresh doubts about its financial viability and governance.

Redivium Limited has successfully completed the formalities for listing a €25 million green bond, aimed at accelerating its sustainable battery recycling projects across Europe, including the UK, Czech Republic, and Romania.

Calix Limited has successfully closed its Share Purchase Plan, raising $2.1 million to complement a prior $20 million institutional placement, strengthening its balance sheet to advance key environmental technology projects.

Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.

Althea Group Holdings Limited has had its trading suspension lifted following a Federal Court ruling related to cleansing notice lodgement failures, marking a key regulatory milestone for the pharmaceutical company.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.